Endothelial Cell News Volume 3.12 | Apr 9 2018

TOP STORY

Heterogeneity in VEGFR3 Levels Drives Lymphatic Vessel Hyperplasia through Cell-Autonomous and Non-Cell-Autonomous Mechanisms

Scientists studied the function of the lymphangiogenic VEGFR3 receptor during embryonic and post-natal development. Inducible genetic deletion of Vegfr3 in lymphatic endothelial cells lead to selection of non-targeted VEGFR3⁺ cells at vessel tips, indicating an indispensable cell-autonomous function in migrating tip cells.. [Nat Commun] Full Article | Press Release

(Ranked by impact factor of the journal)

MPDZ Promotes DLL4-Induced Notch Signaling during Angiogenesis

Tumor angiogenesis was enhanced upon endothelial-specific inactivation of multiple PDZ domain protein (MPDZ) leading to an excessively branched and poorly functional vessel network resulting in tumor hypoxia. [eLife] Full Article

Improved Patency of ePTFE Grafts as a Hemodialysis Access Site after Seeding with Autologous Endothelial Cells Expressing Fibulin 5 and VEGF

Investigators tested the use of ePTFE grafts seeded with autologous endothelial cells (EC) expressing fibulin 5 and VEGF, as a dialysis access site in a porcine model. Seeding ePTFE vascular grafts with genetically modified EC improved long term small caliber graft patency. [Mol Ther] Abstract

Loading miR-210 in Endothelial Progenitor Cells Derived Exosomes Boosts Their Beneficial Effects on Hypoxia/Reoxygeneation-Injured Human Endothelial Cells via Protecting Mitochondrial Function

Researchers showed that endothelial progenitor cell-derived exosomes protect endothelial cells against hypoxia/ reoxygenation injury via improving mitochondrial function and miR-210 enrichment could boost their effects. [Cell Physiol Biochem] Full Article

Mature and Progenitor Endothelial Cells Perform Angiogenesis Also under Protease Inhibition: The Amoeboid Angiogenesis

The authors showed that endothelial cells can move and differentiate into vascular structures in vitro and in vivo also in the absence of proteases activity, performing a new type of neovascularization: the “amoeboid angiogenesis”. [J Exp Clin Cancer Res] Full Article

ETV2-TET1/TET2 Complexes Induce Endothelial Cell-Specific Robo4 Expression via Promoter Demethylation

Researchers demonstrated that the hypermethylated Robo4 proximal promoter is demethylated as human induced pluripotent stem cells differentiate into endothelial cells. [Sci Rep] Full Article

MeCP2-Mediated Epigenetic Regulation in Senescent Endothelial Progenitor Cells

Methyl-CpG-binding protein 2 (MeCP2) reduced angiogenesis of senescent endothelial progenitor cells (EPCs), promoted apoptosis, and caused senescent EPC dysfunction through sirtuin 1 promoter hypermethylation and histone modification. [Stem Cell Res Ther] Full Article

Visualization of Proliferative Vascular Endothelial Cells in Tumors In Vivo by Imaging Their Partner of Sld5-1 Promoter Activity

Investigators generated transgenic mice expressing enhanced green fluorescent protein (EGFP) under the transcriptional control of the DNA replication factor partner of Sld5-1 promoter to assess whether active endothelial cells (ECs) can be distinguished from dormant ECs. [Am J Pathol] Full Article | Press Release

MicroRNA‐181a Inhibits Ocular Neovascularization by Interfering with VEGF Expression

MiR‐181a strongly inhibited in vitro angiogenesis and ex vivo choroidal neovascularization.The strong anti‐angiogenic effect of miR‐181a was displayed on the retinal neovascularization of the in vivo mouse model of oxygen‐induced retinopathy. [Cardiovasc Ther] Abstract

Endothelial Dysfunction, Endothelial Nitric Oxide Bioavailability, Tetrahydrobiopterin, and 5-Methyltetrahydrofolate in Cardiovascular Disease. Where Are We with Therapy?

The authors review endothelial nitric oxide bioavailabilty in relation to endothelial dysfunction as well as the therapeutic strategies involving the nitric oxide synthesis pathway. [Microvasc Res] Abstract

Visit our reviews page to see a complete list of reviews in the endothelial cell research field.

Lilly Announces CYRAMZA^® (Ramucirumab) Phase III REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint

Eli Lilly and Company announced top-line results from its Phase III REACH-2 study of CYRAMZA^® as a single agent in the second-line treatment of people with hepatocellular carcinoma. [Eli Lilly and Company] Press Release

UMN Receives $42.6 Million to Expand Impact on Scientific Health Research

The University of Minnesota’s Clinical and Translational Science Institute received more than $42 million in renewed National Institutes of Health funding through the National Center for Advancing Translational Sciences’ Clinical and Translational Science Award program. [The University of Minnesota] Press Release

Cutting-Edge Cancer Drug Hobbled by Diagnostic Test Confusion

A landmark cancer drug approved last year seemed to herald a long-anticipated change in the treatment of some tumors: with medicines selected on the basis of molecular markers, rather than the tissue in which the cancer first took root. But clinicians and researchers are struggling to put that theory into practice. [Nature News] Editorial

China Asserts Firm Grip on Research Data

In a move few scientists anticipated, the Chinese government has decreed that all scientific data generated in China must be submitted to government-sanctioned data centers before appearing in publications. At the same time, the regulations, posted last week, call for open access and data sharing. [ScienceInsider] Editorial

UK Survey Reveals Widespread Sexual Misconduct by Academic Staff

A survey of current and former UK students has found that 41% experienced sexual misconduct – such as inappropriate comments, unwanted touching or assault – by staff at university. [Nature News] Editorial

Unnecessary Exclusions Shut Patients out of Clinical Trials

The FDA will hold a public meeting in Washington to discuss issues related to clinical trial eligibility criteria. Researchers, study sponsors, patients, and the general public will have an opportunity to share their experiences and tell our regulators why it’s time to revisit the guidelines. [STAT] Editorial

NEW 6^th Annual German Stem Cell Network (GSCN) Conference
September 19-21, 2018
Heidelberg, Germany

Visit our events page to see a complete list of events in the community.

NEW Research Associate – Pulmonary Vascular Signaling and Endothelial Cell Biology (University of Maryland School of Medicine)

Research Associate – Nanomedicine Cellular Targeting and Trafficking (University College London)

Professor – Cell Biology (Universität Münster)

Postdoctoral Fellow/Assistant Staff Scientist – Cardiovascular Biology (Oklahoma Medical Research Foundation)

Doctoral Student Position – Cerebrovascular and Experimental Stroke Research (Karolinska Institutet)

Research Associate – Endothelial Cells (Imperial College London)

Director – Whitaker Cardiovascular Institute (Boston University)

Postdoctoral/Research Associate – Renal and Cardiovascular Research (University of Virginia)

Postdoctoral Fellow & Assistant Research Scientist Positions – Cardiovascular Physiology (University of Arizona College of Medicine)

Postdoctoral Associate – Bioengineering (University of Pittsburgh)

Postdoctoral Research Associate – Vascular Inflammation (University of Illinois)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Endothelial Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.